Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Inflammation

Asthma

Formyl peptide receptor-like 1 (FPRL1; FPR2)

Cell culture studies suggest agonizing FPR2 in innate immune cells could be useful for treating asthma. Patients with severe asthma showed higher levels of active innate immune cells in blood and lungs than healthy controls. In patient-derived innate immune cell cocultures, the FPR2 ligand lipoxin A4 (LXA4) increased NK cell-mediated apoptosis of eosinophils and decreased levels of the inflammatory cytokine IL-13 compared with vehicle. Next steps include clinical testing of LXA4 analogs in models of asthma.

SciBX 6(10); doi:10.1038/scibx.2013.242
Published online March 14, 2013

Patents pending; available for licensing

Barnig, C. et al. Sci. Transl. Med.; published online Feb. 27, 2013;
doi:10.1126/scitranslmed.3004812
Contact: Bruce D. Levy, Brigham and Women's Hospital, Boston, Mass.
e-mail:
blevy@partners.org